Marquet Juan, Velazquez-Kennedy Kyra, López Sandra, Benito Amparo, Blanchard María-Jesús, Garcia-Vela Jose Antonio
Hematology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Pathology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
Hematol Oncol. 2018 Feb;36(1):316-319. doi: 10.1002/hon.2445. Epub 2017 Jun 4.
Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood. Bortezomib-containing treatment protocol was started, but the disease progressed within the chemotherapy. Therefore, treatment with oral valganciclovir was decided and the patient achieved a sustained radiological complete response. HHV8 DNA turned negative 6 months after starting the treatment with valganciclovir.
原发性渗出性淋巴瘤是一种罕见的非霍奇金淋巴瘤，表现为胸腔积液且无肿瘤肿块。它普遍与人类疱疹病毒8型（HHV8）相关，在免疫抑制患者中更为常见。目前尚无标准治疗方法，化疗和抗HIV治疗效果不佳，但仍没有强有力的证据支持使用缬更昔洛韦。我们报告一例HIV阳性男性病例，该患者出现与原发性渗出性淋巴瘤相符的胸腔积液，血液中HHV8 DNA呈阳性。开始使用含硼替佐米的治疗方案，但疾病在化疗过程中进展。因此，决定给予口服缬更昔洛韦治疗，患者获得了持续的影像学完全缓解。在开始使用缬更昔洛韦治疗6个月后，HHV8 DNA转阴。
